[go: up one dir, main page]

DZ2237A1 - 4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number
DZ2237A1
DZ2237A1 DZ970085A DZ970085A DZ2237A1 DZ 2237 A1 DZ2237 A1 DZ 2237A1 DZ 970085 A DZ970085 A DZ 970085A DZ 970085 A DZ970085 A DZ 970085A DZ 2237 A1 DZ2237 A1 DZ 2237A1
Authority
DZ
Algeria
Prior art keywords
preparation
new
pharmaceutical compositions
compositions containing
quinazolinones
Prior art date
Application number
DZ970085A
Other languages
English (en)
Inventor
Mark L Elliot
Wiliiard M Welch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ2237A1 publication Critical patent/DZ2237A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)
DZ970085A 1996-05-15 1997-05-14 4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ2237A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1773896P 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
DZ2237A1 true DZ2237A1 (fr) 2002-12-03

Family

ID=21784266

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970085A DZ2237A1 (fr) 1996-05-15 1997-05-14 4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (39)

Country Link
US (1) US6303615B1 (fr)
EP (1) EP0901487B9 (fr)
JP (1) JP3241388B2 (fr)
KR (1) KR100375155B1 (fr)
CN (2) CN1103772C (fr)
AP (1) AP1148A (fr)
AR (1) AR007118A1 (fr)
AT (1) ATE242232T1 (fr)
AU (1) AU730503B2 (fr)
BG (1) BG102999A (fr)
BR (1) BR9709085A (fr)
CA (1) CA2252907C (fr)
CZ (1) CZ295565B6 (fr)
DE (1) DE69722613T2 (fr)
DK (1) DK0901487T3 (fr)
DZ (1) DZ2237A1 (fr)
EA (1) EA002905B1 (fr)
ES (1) ES2198546T3 (fr)
GT (1) GT199700049A (fr)
HK (1) HK1019607A1 (fr)
HN (1) HN1997000052A (fr)
HR (1) HRP970261B1 (fr)
HU (1) HUP9902148A3 (fr)
ID (1) ID17149A (fr)
IL (1) IL126589A (fr)
IS (1) IS4881A (fr)
MA (1) MA26430A1 (fr)
NO (1) NO985293L (fr)
OA (1) OA10918A (fr)
PL (1) PL330042A1 (fr)
PT (1) PT901487E (fr)
SI (1) SI0901487T1 (fr)
SK (1) SK284108B6 (fr)
TN (1) TNSN97087A1 (fr)
TR (1) TR199802296T2 (fr)
TW (1) TW539675B (fr)
WO (1) WO1997043276A1 (fr)
YU (1) YU19197A (fr)
ZA (1) ZA974156B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3299990B2 (ja) * 1997-02-28 2002-07-08 ファイザー・プロダクツ・インク 神経変性状態およびｃｎｓ外傷関連状態の処置のための３−ヘテロアリール−４（３ｈ）−キナゾリノン類のアトロプ異性体
DE69824157T2 (de) * 1997-02-28 2004-10-14 Pfizer Products Inc., Groton Atropisomere von 3-aryl-4(3h)-chinazolinonen und ihre verwendung als ampa-rezeptor
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
EP0900567A3 (fr) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
ATE324369T1 (de) 1999-02-15 2006-05-15 Eisai Co Ltd Heterodiazinon-derivate
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
KR100869271B1 (ko) 2000-06-12 2008-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-디하이드로피리딘 화합물 및 그의 용도
WO2003043961A2 (fr) * 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulateurs de l'activite de rho c
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
SI3153514T1 (sl) 2004-05-13 2022-02-28 Icos Corporation Kinazolinoni kot zaviralci človeške fosfatidilinozitol 3-kinaze delta
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
CN101355946B (zh) * 2005-11-04 2013-05-08 海德拉生物科学公司 调节trpv3功能的化合物
CA2663436A1 (fr) 2006-10-04 2008-04-10 Pfizer Products Inc. Derives de pyrido[4,3-d]pyrimidin-4(3h)-one utilises en tant qu'antagonistes du recepteur calcique
WO2008140750A1 (fr) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Composés modulant la fonction du trp v3
CA2704710C (fr) * 2007-09-26 2016-02-02 Celgene Corporation Derives de quinazolinone substituee en 6-, 7- ou 8- et compositions en renfermant
JP5291124B2 (ja) 2008-01-30 2013-09-18 シン・プーン・ファーマシューティカル・カンパニー・リミテッド 新規なキナゾリン−２，４−ジオン誘導体、及びこれを含有する脳神経系疾患の予防及び治療用医薬組成物
CN104042618B (zh) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 恶性血液病的治疗
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
EP2421536B1 (fr) 2009-04-20 2015-08-26 Gilead Calistoga LLC Procédés de traitement de tumeurs solides
CA2768843A1 (fr) 2009-07-21 2011-01-27 Gilead Calistoga Llc Traitement de troubles du foie par des inhibiteurs de pi3k
WO2013105985A1 (fr) 2011-02-28 2013-07-18 Philadelphia Health & Education Corporation Inhibiteurs à petites molécules de la recombinase rad51 et procédés associés
AR090253A1 (es) 2012-03-05 2014-10-29 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
MX2016008259A (es) 2013-12-20 2016-10-13 Gilead Calistoga Llc Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
EP3154960A1 (fr) 2014-06-13 2017-04-19 Gilead Sciences, Inc. Inhibiteurs de la phosphatidylinositol 3-kinase
WO2020124090A1 (fr) 2018-12-14 2020-06-18 Eisai R&D Management Co., Ltd. Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine
WO2021154966A1 (fr) 2020-01-29 2021-08-05 Kamari Pharma Ltd. Composés et compositions pour leur utilisation dans le traitement de troubles cutanés
CN113831335A (zh) * 2020-06-24 2021-12-24 北京大学 吡啶[2,3-d]并嘧啶-4-(3H)-酮类化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (fr) 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Quinazolones substituees a activite anticonvulsivante
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
CA2162023A1 (fr) 1993-05-06 1994-11-24 Poul Jacobsen Composes a base de [1,2,4]triazolo[4,3-a]quinoxaline; preparation et utilisation
GB9400680D0 (en) 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
DE69824157T2 (de) 1997-02-28 2004-10-14 Pfizer Products Inc., Groton Atropisomere von 3-aryl-4(3h)-chinazolinonen und ihre verwendung als ampa-rezeptor

Also Published As

Publication number Publication date
IL126589A (en) 2003-06-24
JP3241388B2 (ja) 2001-12-25
DK0901487T3 (da) 2003-08-25
CN1420114A (zh) 2003-05-28
HUP9902148A3 (en) 2002-11-28
JPH11514663A (ja) 1999-12-14
OA10918A (en) 2001-10-25
YU19197A (sh) 1999-09-27
CA2252907C (fr) 2005-05-17
CA2252907A1 (fr) 1997-11-20
SI0901487T1 (en) 2003-10-31
GT199700049A (es) 1998-10-21
EA002905B1 (ru) 2002-10-31
HN1997000052A (es) 1997-06-26
AU1554997A (en) 1997-12-05
PT901487E (pt) 2003-08-29
EA199800923A1 (ru) 1999-06-24
PL330042A1 (en) 1999-04-26
TR199802296T2 (xx) 1999-02-22
BG102999A (en) 1999-09-30
HRP970261B1 (en) 2003-06-30
ES2198546T3 (es) 2004-02-01
CN1218464A (zh) 1999-06-02
CN1103772C (zh) 2003-03-26
KR20000011054A (ko) 2000-02-25
NO985293L (no) 1999-01-13
EP0901487B1 (fr) 2003-06-04
ID17149A (id) 1997-12-04
HUP9902148A2 (hu) 2000-04-28
EP0901487A1 (fr) 1999-03-17
EP0901487B9 (fr) 2004-09-29
DE69722613D1 (de) 2003-07-10
HRP970261A2 (en) 2000-12-31
WO1997043276A1 (fr) 1997-11-20
AP9701003A0 (en) 1997-07-31
CZ352698A3 (cs) 1999-11-17
AR007118A1 (es) 1999-10-13
DE69722613T2 (de) 2004-05-13
MA26430A1 (fr) 2004-12-20
TNSN97087A1 (fr) 2005-03-15
SK284108B6 (sk) 2004-09-08
BR9709085A (pt) 1999-08-03
HK1019607A1 (en) 2000-02-18
AP1148A (en) 2003-02-28
TW539675B (en) 2003-07-01
CZ295565B6 (cs) 2005-08-17
AU730503B2 (en) 2001-03-08
IL126589A0 (en) 1999-08-17
IS4881A (is) 1998-10-27
ZA974156B (en) 1998-11-16
ATE242232T1 (de) 2003-06-15
NO985293D0 (no) 1998-11-13
KR100375155B1 (ko) 2003-08-19
SK152098A3 (en) 2000-05-16
US6303615B1 (en) 2001-10-16

Similar Documents

Publication Publication Date Title
DZ2237A1 (fr) 4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA24484A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant .
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2465A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
MA26598A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur préparation et compositions pharmaceutiques les contenant
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2128A1 (fr) Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2694290B1 (fr) Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
MA23899A1 (fr) Procede pour la preparation de derives de pyrimidinedione et -trione, triazinedione et quinazolinedione, procede de preparation de compositions pharmaceutiques les contenant et leur utilisation
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
FR2740136B1 (fr) Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26414A1 (fr) Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant.
DZ2923A1 (fr) Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.
DZ2074A1 (fr) Formulation nouvelle contenant de la paroxétine, et procédé pour sa préparation.